Alto Neuroscience
@AltoNeuro
Followers
1K
Following
91
Media
377
Statuses
460
Advancing the most robust #PrecisionPsychiatry pipeline to bring every person suffering from a mental health condition the right treatment, right away.
Mountain View, CA
Joined January 2020
Today, @AltoNeuro reported financial results for the quarter ended September 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. Learn more here: https://t.co/6QuulRXELs
0
1
7
A proud day for Alto Neuroscience at the @NYSE. We rang the Opening Bell today to celebrate our ongoing commitment to transforming the treatment of mental health disorders through precision psychiatry.
1
10
19
Excited to join the conversation at upcoming investor conferences! Stifel 2025 Healthcare Conf. – Nov 12, 10:00 AM ET, NYC Jefferies London Healthcare Conf. – Nov 17, 3:30 PM GMT Webcasts: https://t.co/MVtvgkDlIA Read more here: https://t.co/CqbBqmhzFw
#Biotech #Neuroscience
0
0
5
@AltoNeuro is pleased to announce the close of a $50 million private placement financing. Read more here: https://t.co/pks5kbmGZK
#TRD #financing #biotech #neuroscience #precisionpsychiatry
0
3
10
@AltoNeuro announced today that it will accelerate the development of ALTO-207 for people with treatment-resistant depression (TRD), following a successful outcome from a recent meeting with @FDA. https://t.co/kzwKlPpRbb
#TRD #biotech #neuroscience
2
1
20
At #ECNP2025, Dr. Mike Browning presented key results previously reported in The Lancet from the PAX-D study. These results guided Alto’s acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole.
0
0
6
This #WorldMentalHealthDay, the focus is “Access to Services: Mental Health in Catastrophes and Emergencies.” At @AltoNeuro, we’re advancing neuroscience to make effective, personalized mental health care available to all. #MentalHealthAwareness #Neuroscience #AccessToCare
0
0
7
Encouraging news from @AltoNeuro: the @US_FDA has granted Fast Track designation to ALTO-101 for treating cognitive impairment in schizophrenia (CIAS). No approved therapies exist today—together, we’re working to change that. Learn more here: https://t.co/GTc77fN5df
#FastTrack
1
9
20
Grateful to @PrecMedOnline for highlighting @AltoNeuro's mission: bringing precision psychiatry to patients through EEG biomarkers. Our goal is simple — the right treatment, for the right patient, at the right time. Learn more here: https://t.co/kWVS6Ilr2o
#PrecisionMedicine
precisionmedicineonline.com
By leveraging EEG biomarkers, Alto Neuroscience seeks to target patient subgroups in psychiatry by matching therapies to biology.
1
1
9
We're in the spotlight! Our CEO, Amit Etkin, MD, PhD, shares how we’re advancing drug development for cognitive impairment in schizophrenia, plus new EEG biomarker insights. ▶️ Video: https://t.co/1AoCgmrWUy 📰Article: https://t.co/8f1Sd2BSfN
#Schizophrenia #Neuroscience
0
3
11
This week, our CEO, @AmitEtkin, will discuss Alto’s recent corporate updates during a fireside chat at TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. Tune in here: https://t.co/kpMTa5wKR6
0
0
4
Meet Kelsey Dock, Senior Clinical Research Associate at Alto. Kelsey plays a key role in bridging scientific innovation with real human impact, helping to advance our mission to develop precision psychiatry treatments that are more effective, accessible, and personalized.
0
0
2
We’re heading to New York City! Our CEO, @AmitEtkin, will discuss Alto’s recent corporate updates during upcoming investor conferences. Learn more: https://t.co/vALm6ElNji
0
1
8
The future of mental health is here as @AltoNeuro is ditching trial-and-error for precision care. Founder & CEO @AmitEtkin joins @ICEHousePodcast to share how science is replacing guesswork. 📺 YouTube: https://t.co/XfO0fco5Mf 🎧 Spotify: https://t.co/wqmDosEhQL ➡️ Follow
9
5
19
Our CEO, @AmitEtkin, will discuss Alto’s recent corporate updates during upcoming investor conferences. Learn more: https://t.co/vALm6ElftK
0
1
9
Today, we reported our second quarter 2025 financial results and key business highlights. Read more in our press release here: https://t.co/XeI5DgNmbo
0
0
4
We’re excited to welcome Raymond Sanchez, M.D., to Alto’s Board of Directors, a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. Welcome, Ray! Read more here: https://t.co/KVb7CATCwZ
0
1
9
Our CMO Dr. Adam Savitz shared insights with @DrugTargetRev on how our biomarker-driven Precision Psychiatry Platform™ aims to transform #neuropsychiatric treatment. To learn more about our #PrecisionPsychiatry approach, read the article here: https://t.co/MlqbGnMrax
drugtargetreview.com
Discover the essential role of biomarkers in early drug development from patient selection to trial design in our report.
1
0
6
ICYMI, Our CEO, @AmitEtkin sat down with @BiotechTV to discuss Alto’s biomarker-driven #PrecisionPsychiatryPlatform and how we’re using #AI and #MachineLearning across our clinical-stage development programs. Watch the full video here:
biotechtv.com
Amit Etkin says Alto Neuro is trying to use machine learning to understand signals from the complexity of the brain, and the company is also embedding AI in its clinical trials in order to collect as...
1
0
5
Last week, our CEO @AmitEtkin joined #NYSEFloorTalk to share how Alto is advancing a new era of precision psychiatry and how we’re using #MachineLearning and #AI across our clinical-stage pipeline. Thank you, @NYSE for the opportunity to share our story:
tv.nyse.com
0
1
4